116 related articles for article (PubMed ID: 19596935)
1. Pseudoprogression and MGMT status in glioblastoma patients: implications in clinical practice.
Fabi A; Russillo M; Metro G; Vidiri A; Di Giovanni S; Cognetti F
Anticancer Res; 2009 Jul; 29(7):2607-10. PubMed ID: 19596935
[TBL] [Abstract][Full Text] [Related]
2. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
Brandes AA; Franceschi E; Tosoni A; Blatt V; Pession A; Tallini G; Bertorelle R; Bartolini S; Calbucci F; Andreoli A; Frezza G; Leonardi M; Spagnolli F; Ermani M
J Clin Oncol; 2008 May; 26(13):2192-7. PubMed ID: 18445844
[TBL] [Abstract][Full Text] [Related]
3. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.
Brandsma D; Stalpers L; Taal W; Sminia P; van den Bent MJ
Lancet Oncol; 2008 May; 9(5):453-61. PubMed ID: 18452856
[TBL] [Abstract][Full Text] [Related]
4. Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide.
Weiler M; Hartmann C; Wiewrodt D; Herrlinger U; Gorlia T; Bähr O; Meyermann R; Bamberg M; Tatagiba M; von Deimling A; Weller M; Wick W
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):670-6. PubMed ID: 19836157
[TBL] [Abstract][Full Text] [Related]
5. [Significant regression of glioblastoma with low level of Mgmt gene expression following radiotherapy].
Matsko MV; Luchin EI; Ievleva AG; Bakholdin DV; Abysheva SN; Zavgorodniaia EV; Potapova ON; Imianitov EN; Ulitin AIu; Matsko DE
Vopr Onkol; 2011; 57(2):245-9. PubMed ID: 21809674
[TBL] [Abstract][Full Text] [Related]
6. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
[TBL] [Abstract][Full Text] [Related]
7. MGMT in primary and recurrent human glioblastomas after radiation and chemotherapy and comparison with p53 status and clinical outcome.
Wiewrodt D; Nagel G; Dreimüller N; Hundsberger T; Perneczky A; Kaina B
Int J Cancer; 2008 Mar; 122(6):1391-9. PubMed ID: 18000822
[TBL] [Abstract][Full Text] [Related]
8. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Stupp R; Hegi ME; Mason WP; van den Bent MJ; Taphoorn MJ; Janzer RC; Ludwin SK; Allgeier A; Fisher B; Belanger K; Hau P; Brandes AA; Gijtenbeek J; Marosi C; Vecht CJ; Mokhtari K; Wesseling P; Villa S; Eisenhauer E; Gorlia T; Weller M; Lacombe D; Cairncross JG; Mirimanoff RO; ;
Lancet Oncol; 2009 May; 10(5):459-66. PubMed ID: 19269895
[TBL] [Abstract][Full Text] [Related]
9. An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging.
Drabycz S; Roldán G; de Robles P; Adler D; McIntyre JB; Magliocco AM; Cairncross JG; Mitchell JR
Neuroimage; 2010 Jan; 49(2):1398-405. PubMed ID: 19796694
[TBL] [Abstract][Full Text] [Related]
10. Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin.
Park CK; Park SH; Lee SH; Kim CY; Kim DW; Paek SH; Kim DG; Heo DS; Kim IH; Jung HW
Neuropathology; 2009 Aug; 29(4):443-9. PubMed ID: 19170894
[TBL] [Abstract][Full Text] [Related]
11. Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: a radiographic study in 358 de novo human glioblastomas.
Ellingson BM; Cloughesy TF; Pope WB; Zaw TM; Phillips H; Lalezari S; Nghiemphu PL; Ibrahim H; Naeini KM; Harris RJ; Lai A
Neuroimage; 2012 Jan; 59(2):908-16. PubMed ID: 22001163
[TBL] [Abstract][Full Text] [Related]
12. The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas.
Cao VT; Jung TY; Jung S; Jin SG; Moon KS; Kim IY; Kang SS; Park CS; Lee KH; Chae HJ
Neurosurgery; 2009 Nov; 65(5):866-75; discussion 875. PubMed ID: 19834398
[TBL] [Abstract][Full Text] [Related]
13. Radiological model based on the standard magnetic resonance sequences for detecting methylguanine methyltransferase methylation in glioma using texture analysis.
Huang WY; Wen LH; Wu G; Pang PP; Ogbuji R; Zhang CC; Chen F; Zhao JN
Cancer Sci; 2021 Jul; 112(7):2835-2844. PubMed ID: 33932065
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme.
Metro G; Fabi A; Mirri MA; Vidiri A; Pace A; Carosi M; Russillo M; Maschio M; Giannarelli D; Pellegrini D; Pompili A; Cognetti F; Carapella CM
Cancer Chemother Pharmacol; 2010 Jan; 65(2):391-7. PubMed ID: 19847425
[TBL] [Abstract][Full Text] [Related]
15. Local intracerebral administration of O(6)-benzylguanine combined with systemic chemotherapy with temozolomide of a patient suffering from a recurrent glioblastoma.
Koch D; Hundsberger T; Boor S; Kaina B
J Neurooncol; 2007 Mar; 82(1):85-9. PubMed ID: 17031555
[TBL] [Abstract][Full Text] [Related]
16. Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial.
Schaub C; Kebir S; Junold N; Hattingen E; Schäfer N; Steinbach JP; Weyerbrock A; Hau P; Goldbrunner R; Niessen M; Mack F; Stuplich M; Tzaridis T; Bähr O; Kortmann RD; Schlegel U; Schmidt-Graf F; Rohde V; Braun C; Hänel M; Sabel M; Gerlach R; Krex D; Belka C; Vatter H; Proescholdt M; Herrlinger U; Glas M
J Cancer Res Clin Oncol; 2018 Aug; 144(8):1581-1589. PubMed ID: 29808316
[TBL] [Abstract][Full Text] [Related]
17. [MGMT and temozolomide sensibility].
Tabouret E
Bull Cancer; 2021 Dec; 108(12):1075-1076. PubMed ID: 34782119
[No Abstract] [Full Text] [Related]
18. Association between response to primary treatments and MGMT status in glioblastoma.
Franceschi E; Tosoni A; Pozzati E; Brandes AA
Expert Rev Anticancer Ther; 2008 Nov; 8(11):1781-6. PubMed ID: 18983238
[TBL] [Abstract][Full Text] [Related]
19. Glioblastoma treated with concurrent radiation therapy and temozolomide chemotherapy: differentiation of true progression from pseudoprogression with quantitative dynamic contrast-enhanced MR imaging.
Yun TJ; Park CK; Kim TM; Lee SH; Kim JH; Sohn CH; Park SH; Kim IH; Choi SH
Radiology; 2015 Mar; 274(3):830-40. PubMed ID: 25333475
[TBL] [Abstract][Full Text] [Related]
20. Repair mechanisms help glioblastoma resist treatment.
Atkins RJ; Ng W; Stylli SS; Hovens CM; Kaye AH
J Clin Neurosci; 2015 Jan; 22(1):14-20. PubMed ID: 25444993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
